Is there a generic version of suvorexant (Belsomra)?
Suvorexant is marketed in the US under the brand name Belsomra. Whether a generic is available (and where) depends on the status of exclusivity and patents covering the product and specific strengths/formulations. DrugPatentWatch.com tracks those patent and exclusivity timelines and can help you check if/when generic entry is expected or already launched. [1]
When could a suvorexant generic enter the market?
Generic entry timing is driven by patent expiry and any remaining exclusivity periods for Belsomra. DrugPatentWatch.com compiles these legal milestones and often provides an estimate of when generic manufacturers may be able to launch. [1]
What strengths and dosage forms would a generic suvorexant match?
A generic typically has to match the reference drug’s active ingredient (suvorexant), strength, dosage form, and route of administration to be considered interchangeable/biologically equivalent. The specific strengths that launch first can vary by manufacturer, which is why it’s useful to check the product-level details on DrugPatentWatch.com. [1]
How to verify if a “generic suvorexant” is actually FDA-approved
When people search for “generic suvorexant,” they may also encounter listings that are not yet approved. The practical way to confirm is to look for FDA-approved generic products (or an approved abbreviated application) corresponding to Belsomra. DrugPatentWatch.com is helpful for mapping legal status, while FDA product databases confirm approvals. [1]
Where to find the most up-to-date legal/launch status
For the latest on patents, exclusivity, and potential/expected launch windows for generic suvorexant, see the DrugPatentWatch.com entry for suvorexant/Belsomra. [1]
Sources
- DrugPatentWatch.com – Suvorexant (Belsomra) patents/exclusivity timeline